The prevalence and clinical significance of perinuclear anti-neutrophil cytoplasmic antibody in Korean patients with ulcerative colitis

Digestive Diseases and Sciences

Volumn 55, Issue 5, 2010, Pages 1406-1412

  Lee, Jin Ha ^a   Cheon, Jae Hee ^a   Kim, Eun Soo ^a   Chung, Moon Jae ^a   Kang, Wonseok ^a   Kim, Duk Hwan ^a   Ha, You Jung ^a   Park, Jae Jun ^a   Kim, Tae Il ^a   Kim, Won Ho ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Disease activity; Korean; PANCA; Prevalence; Ulcerative colitis

Indexed keywords

CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; NEUTROPHIL CYTOPLASMIC ANTIBODY;

AGGRESSIVENESS; ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FOLLOW UP; HOSPITAL; HUMAN; KOREA; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; PREVALENCE; PRIORITY JOURNAL; PROCTITIS; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RECURRENCE RISK; RELAPSE; ULCERATIVE COLITIS; ADULT; CHI SQUARE DISTRIBUTION; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOLOGY;

ADULT; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; CHI-SQUARE DISTRIBUTION; COLITIS, ULCERATIVE; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; KOREA; MALE; PREVALENCE;

EID: 77953623153     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-009-0847-8     Document Type: Article

References (35)

1. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology. 1998;115:182-205. doi:10.1016/S0016-5085(98)70381-6. (Pubitemid 28307304)
2. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347:417-429. doi:10.1056/NEJMra020831. (Pubitemid 34851835)
3. Roozendaal C, Kallenberg CG. Are anti-neutrophil cytoplasmic antibodies (ANCA) clinically useful in inflammatory bowel disease (IBD)? Clin Exp Immunol. 1999;116:206-213. doi: 10.1046/j.1365-2249.1999.00905.x. (Pubitemid 29219714)
4. Saxon A, Shanahan F, Landers C, Ganz T, Targan S. A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. J Allergy Clin Immunol. 1990;86: 202-210. doi:10.1016/S0091-6749(05) 80067-3. (Pubitemid 20288725)
5. Rump JA, Scholmerich J, Gross V, Roth M, Helfesrieder R, Rautmann A, Lüdemann J, Gross WL, Peter HH. A new type of perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) in active ulcerative colitis but not in Crohn's disease. Immunobiology. 1990;181:406-413.
6. Saibeni S, Folli C, de Franchis R, Borsi G, Vecchi M. Diagnostic role and clinical correlates of anti-saccharomyces cerevisiae antibodies (ASCA) and anti-neutrophil cytoplasmic antibodies (p-ANCA) in Italian patients with inflammatory bowel diseases. Dig Liver Dis. 2003;35:862-868. doi:10.1016/j.dld.2003.07.001. (Pubitemid 41070491)
7. Bosch X, Guilabert A, Font J. Antineutrophil cytoplasmic antibodies. Lancet. 2006;368:404-418. doi:10.1016/S0140-6736(06)69114-9. (Pubitemid 44108124)
8. Sobajima J, Ozaki S, Okazaki T, Osakada F, Sumita S, Mori K, Nakao K. Anti-neutrophil cytoplasmic antibodies (ANCA) in ulcerative colitis: anti-cathepsin G and a novel antibody correlate with a refractory type. Clin Exp Immunol. 1996;105:120-124. doi:10.1046/j.1365-2249.1996.d01-724.x.
9. Sandborn WJ, Landers CJ, Tremaine WJ, Targan SR. Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: results of a pilot study. Mayo Clin Proc. 1996;71:431-436. doi:10.4065/71.5.431.
10. Oudkerk Pool M, Ellerbroek PM, Ridwan BU, Goldschmeding R, von Blomberg BM, Peña AS, Dolman KM, Bril H, Dekker W, Nauta JJ. Serum antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease are mainly associated with ulcerative colitis. A correlation study between perinuclear antineutrophil cytoplasmic autoantibodies and clinical parameters, medical, and surgical treatment. Gut. 1993;34:46-50. doi:10.1136/gut.34.1.46.
11. O'Morain C, Tobin A, Leen E, Suzuki Y, O'Riordan T. Criteria of case definition in Crohn's disease and ulcerative colitis. Scand J Gastroenterol Suppl. 1989;170:7-11. doi:10.3109/00365528909091340. discussion 16-19
12. Powell-Tuck J, Bown RL, Lennard-Jones JE. A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis. Scand J Gastroenterol. 1978;13:833-837.
13. D'Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, Lémann M, Marteau P, Rutgeerts P, Schölmerich J, Sutherland LR. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132:763-786. doi:10.1053/j.gastro.2006.12.038.
14. Reddy D, Murphy SJ, Kane SV, Present DH, Kornbluth AA. Relapses of inflammatory bowel disease during pregnancy: inhospital management and birth outcomes. Am J Gastroenterol. 2008;103:1203-1209. doi:10.1111/j.1572-0241.2007. 01756.x. (Pubitemid 351677969)
15. Wang YF, Zhang H, Ouyang Q. Clinical manifestations of inflammatory bowel disease: East and West differences. J Dig Dis. 2007;8:121-127. doi:10.1111/j.1443-9573.2007.00296.x. (Pubitemid 47161783)
16. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749-753. doi:10.1136/gut.2005.082909. (Pubitemid 43764536)
17. Kuriyama M, Kato J, Fujimoto T, Nasu J, Miyaike J, Morita T, Okada H, Suzuki S, Shiode J, Yamamoto H, Shiratori Y. Risk factors and indications for colectomy in ulcerative colitis patients are different according to patient's clinical background. Dis Colon Rectum. 2006;49:1307-1315. doi:10.1007/s10350- 006-0574-6. (Pubitemid 44401378)
18. Abad E, Tural C, Mirapeix E, Cuxart A. Relationship between ANCA and clinical activity in inflammatory bowel disease: variation in prevalence of ANCA and evidence of heterogeneity. J Autoimmun. 1997;10:175-180. doi:10.1006/jaut.1996.0114. (Pubitemid 27242458)
19. Lok KH, Hung HG, Ng CH, Kwong KC, Yip WM, Lau SF, Li KK, Li KF, Szeto ML. Epidemiology and clinical characteristics of ulcerative colitis in Chinese population: experience from a single center in Hong Kong. J Gastroenterol Hepatol. 2008;23: 406-410. doi:10.1111/j.1440-1746.2007.05079.x. (Pubitemid 351342064)
20. Osangthamnont C, Manatsathit S, Pongprasopchai S, Viriyataveekul R, Chaihirunkarn S, Leelakusolvong S, Boonyapisit S. Antibodies to neutrophil cytoplasma in patients with ulcerative colitis and their first-degree relatives in Thailand. J Gastroenterol Hepatol. 2001;16:866-871. doi:10.1046/j.1440-1746. 2001.02546.x. (Pubitemid 32868630)
21. Yamamoto-Furusho JK, Takahashi-Monroy T, Vergara-Fernandez O, Reyes E, Uscanga L. Perinuclear anti-neutrophil cytoplasmic antibodies (P-ANCA) in chronic ulcerative colitis: experience in a Mexican Institution. World J Gastroenterol. 2006;12:3406-3409.
22. Sung JY, Chan KL, Hsu R, Liew CT, Lawton JW. Ulcerative colitis and antineutrophil cytoplasmic antibodies in Hong Kong Chinese. Am J Gastroenterol. 1993;88:864-869.
23. Perri F, Annese V, Piepoli A, Napolitano G, Lombardi G, Ciavarella G, Di Giorgio G, Andriulli A. HLA antigens and pANCA define ulcerative colitis as a genetically heterogeneous disorder. Ital J Gastroenterol Hepatol. 1998;30:56-61.
24. Duerr RH, Neigut DA. Molecularly defined HLA-DR2 alleles in ulcerative colitis and an antineutrophil cytoplasmic antibodypositive subgroup. Gastroenterology. 1995;108:423-427. doi: 10.1016/0016-5085(95)90069-1.
25. Yang H, Rotter JI, Toyoda H, Landers C, Tyran D, McElree CK, Targan SR. Ulcerative colitis: a genetically heterogeneous disorder defined by genetic (HLA class II) and subclinical (antineutrophil cytoplasmic antibodies) markers. J Clin Invest. 1993;92: 1080-1084. doi:10.1172/JCI116613.
26. Park SH, Kim YM, Yang SK, Kim SH, Byeon JS, Myung SJ, Cho YK, Yu CS, Choi KS, Chung JW, Kim B, Choi KD, Kim JH. Clinical features and natural history of ulcerative colitis in Korea. Inflamm Bowel Dis. 2007;13:278-283. doi:10.1002/ibd.20015. (Pubitemid 46465908)
27. Maunder RG, Lancee WJ, Greenberg GR, Hunter JJ, Fernandes BJ. Insecure attachment in a subgroup with ulcerative colitis defined by ANCA status. Dig Dis Sci. 2000;45:2127-2132. doi: 10.1023/A:1026471303921. (Pubitemid 32063180)
28. Maunder RG, Greenberg GR, Hunter JJ, Lancee WJ, Steinhart AH, Silverberg MS. Psychobiological subtypes of ulcerative colitis: pANCA status moderates the relationship between disease activity and psychological distress. Am J Gastroenterol. 2006; 101:2546-2551.
29. Fujimoto T, Kato J, Nasu J, Kuriyama M, Okada H, Yamamoto H, Mizuno M, Shiratori Y; Japan West Ulcerative Colitis (JWUC) Study Group. Change of clinical characteristics of ulcerative colitis in Japan: analysis of 844 hospital-based patients from 1981 to 2000. Eur J Gastroenterol Hepatol. 2007;19:229-235. doi:10.1097/MEG.0b013e3280110fb9.
30. Ouyang Q, Tandon R, Goh KL, Ooi CJ, Ogata H, Fiocchi C. The emergence of inflammatory bowel disease in the Asian Pacific region. Curr Opin Gastroenterol. 2005;21:408-413.
31. Jiang XL, Cui HF. An analysis of 10218 ulcerative colitis cases in China. World J Gastroenterol. 2002;8:158-161.
32. Radhakrishnan S, Zubaidi G, Daniel M, Sachdev GK, Mohan AN. Ulcerative colitis in Oman. A prospective study of the incidence and disease pattern from 1987 to 1994. Digestion. 1997;58:266-270. doi:10.1159/000201453.
33. Benfield GF, Montgomery RD, Asquith P. Ulcerative colitis in Asian immigrants. Postgrad Med J. 1987;63:629-635. doi: 10.1136/pgmj.63.742.629.
34. Kane SV, Sable K, Hanauer SB. The menstrual cycle and its effect on inflammatory bowel disease and irritable bowel syndrome: a prevalence study. Am J Gastroenterol. 1998;93:1867-1872. doi:10.1111/j.1572-0241.1998.540-i.x.
35. Kane SV, Reddy D. Hormonal replacement therapy after menopause is protective of disease activity in women with inflammatory bowel disease. Am J Gastroenterol. 2008;103:1193-1196. doi:10.1111/j.1572-0241.2007.01700.x. (Pubitemid 351677960)